Takeda gains first European approval for lurasidone

14 August 2013

Japan’s largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland’s regulator Swissmedic for lurasidone, its once-daily antipsychotic for the treatment of patients with schizophrenia.

This is the first registration in Europe for lurasidone, which was originally developed by fellow Japanese drug major Dainippon Sumitomo Pharmaceutical (TYO: 4506) and is already marketed as Latuda for both schizophrenia and bipolar depression in the USA and Canada by Dainippon's subsidiary Sunovion. The drug was recently approved by the US Food and Drug Administration (The Pharma Letter July 2) and was accepted for review by the European Medicines Agency in October 2012.

Takeda licensed exclusive commercialisation rights to lurasidone for 26 member states of the European, excluding the UK and Norway, as well as Switzerland, Turkey, and Russia (TPL April 1, 2011).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK